Trials / Not Yet Recruiting
Not Yet RecruitingNCT06900478
Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for Hepatocellular Carcinoma With High-Risk Recurrence Factors:A Single-Center, Prospective Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Hua Li · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single-center, phase II study，to evaluate the efficacy and safety of icariin soft capsules combined with TACE as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after resection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Icariin Soft Capsules+TACE | TACE: perform preoperative infusion chemotherapy, then selectively inject 2 to 5 mL of iodized oil and embolize. Icariin Soft Capsules：take 6 tablets each time, orally, twice a day. |
Timeline
- Start date
- 2025-03-30
- Primary completion
- 2026-06-01
- Completion
- 2027-02-28
- First posted
- 2025-03-28
- Last updated
- 2025-03-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06900478. Inclusion in this directory is not an endorsement.